Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given an average recommendation of “Moderate Buy” by the twenty-three brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $170.41.

A number of brokerages recently issued reports on SRPT. HC Wainwright restated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Scotiabank began coverage on shares of Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price on the stock. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada dropped their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in SRPT. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after buying an additional 117,904 shares in the last quarter. Capital International Investors lifted its position in Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Janus Henderson Group PLC lifted its position in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Farallon Capital Management LLC lifted its position in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after purchasing an additional 285,100 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 1.2 %

SRPT stock opened at $97.19 on Monday. The company’s 50 day simple moving average is $111.73 and its 200-day simple moving average is $119.82. The firm has a market capitalization of $9.43 billion, a PE ratio of 77.75 and a beta of 0.79. Sarepta Therapeutics has a 12 month low of $97.06 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.